Human IL-29/IFN-lambda 1 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF1598
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Gly20-Thr200
Accession # Q8IU54
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human IL-29/IFN-lambda 1 Antibody
IL‑29/IFN-lambda 1 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑29/IFN-lambda 1 Antibody.
Recombinant Human IL-29/ IFN-lambda 1 (Catalog # 1598-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepato-cellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-29/IFN-lambda 1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-29/IFN-lambda 1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1598). The ND50 is typically 0.2-1.0 µg/mL.Applications for Human IL-29/IFN-lambda 1 Antibody
Western Blot
Sample: Recombinant Human IL-29/IFN-lambda 1 (Catalog # 1598-IL)
Neutralization
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-29/IFN-lambda 1
IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL‑29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.
References
- Vilcek, J. (2003) Nature Immunol. 4:8.
- Sheppard, P. et al. (2003) Nature Immunol. 4:63.
- Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional IL-29/IFN-lambda 1 Products
Product Documents for Human IL-29/IFN-lambda 1 Antibody
Product Specific Notices for Human IL-29/IFN-lambda 1 Antibody
For research use only